Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Brochstein is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]

Industry Overview - The cannabis sector has faced a prolonged slump due to the lack of federal reforms, but recent comments from President Trump regarding marijuana rescheduling have sparked renewed optimism, leading to a surge in share prices [1] - A potential federal reclassification could significantly transform the industry by easing tax burdens, improving access to banking services, and facilitating broader medical and recreational adoption, with the market expected to exceed $160 billion by 2032 [2] Company Analysis: Village Farms International (VFF) - Village Farms International holds a Zacks Rank 1 and is one of the few cannabis operators consistently generating positive EBITDA and cash flow, with Q2 earnings showing a 690% year-over-year increase in international medical export sales [4][6] - The company has divested its lower-margin fresh-produce business to focus on higher-margin cannabis operations, maintaining its position as one of Canada's top three cannabis players and contributing $2.4 million in incremental Q2 revenues from shipments to the Netherlands [5] - EPS estimates for VFF have improved significantly, with 2025 estimates rising from a loss of 9 cents to earnings of 12 cents, and the stock has increased nearly 274% year to date [6] Company Analysis: Canopy Growth (CGC) - Canopy Growth, with a Zacks Rank 2, has been streamlining operations by exiting lower-margin businesses and selling non-core assets to enhance liquidity and reduce operating expenses [7] - The company's U.S. strategy through Canopy USA provides exposure to key recreational and medical cannabis markets, and federal rescheduling could accelerate the commercialization of its U.S. assets, creating new revenue streams [8] - Loss per share estimates for CGC have narrowed from 57 cents to 50 cents for 2025, and despite a 55% decline in stock price year to date, improvements in top- and bottom-line metrics are encouraging for investors [9] Company Analysis: High Tide (HITI) - High Tide, also holding a Zacks Rank 2, is recognized as one of Canada's fastest-growing cannabis retailers, operating over 170 branded retail locations and leveraging both physical and online sales channels [10] - Loss per share estimates for HITI have improved from 5 cents to 4 cents for 2025, with 2026 EPS rising from 5 cents to 11 cents, and the stock has seen a 9% increase, driven by strong operational performance and optimism regarding federal marijuana rescheduling [11][12]

Core Viewpoint - Tilray Brands has experienced a significant stock price increase of over 133% in the last three months, driven by investor anticipation of a potential U.S. government decision to reclassify cannabis, which could transform the financial landscape of the industry [1][3][10] Company Performance - Tilray reported a surprise adjusted profit of 2 cents per share in its fourth quarter 2025 earnings report, despite a substantial GAAP net loss of $2.18 billion for the fiscal year [2][10] - The stock price forecast for Tilray is set at an average of $1.92, indicating a potential upside of 76.65% from the current price of $1.09 [9] Industry Context - The anticipated reclassification of cannabis from Schedule I to Schedule III by the U.S. Drug Enforcement Administration (DEA) is seen as a pivotal regulatory change that would acknowledge its medical use and reduce perceived risks [4][5] - This reclassification would eliminate the burdensome Section 280E of the U.S. tax code, which currently prevents cannabis businesses from deducting normal operating expenses, leading to effective tax rates exceeding 70% [6][7] Investment Appeal - Tilray has become a preferred investment vehicle for speculating on the potential benefits of cannabis reclassification due to its strategic positioning, market access, and financial stability [8][10] - The company has a market capitalization of $1.17 billion and high trading volume, making it accessible to a wide range of investors [12] - Tilray's diversified operations, including its beverage alcohol segment and wellness division, position it well for future growth in a healthier U.S. cannabis market [12] Management Confidence - Recent insider purchases by CEO Irwin D. Simon and CFO Carl A. Merton indicate strong management confidence in the company's direction and potential [10]

Core Viewpoint - EnWave Corporation successfully closed a private placement offering, raising C$3,000,000 through the issuance of 7,500,000 common shares at C$0.40 per share [1][2]. Group 1: Offering Details - The offering included a brokered component of 6,125,000 shares and a non-brokered component of 1,375,000 shares [2]. - Clarus Securities Inc. acted as the lead agent and sole bookrunner for the brokered component of the offering [2]. - The offering was conducted under the Listed Issuer Financing Exemption, allowing for the issuance of shares without a hold period, except for a four-month hold on shares received by directors and officers [3]. Group 2: Financial Aspects - Clarus received a cash commission of C$134,750 and 336,875 non-transferrable compensation options, each allowing the acquisition of one share at the issue price for 24 months [4]. - The net proceeds from the offering will be used to build two large-scale Radiant Energy Vacuum (REV™) dehydration machines, with a manufacturing timeline of approximately six months [5]. Group 3: Related Party Transactions - The offering involved a related party transaction, with certain directors and senior officers subscribing for a total of 212,500 shares [6]. - The company relied on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's value being below 25% of the company's market capitalization [6]. Group 4: Company Overview - EnWave is a leader in vacuum microwave dehydration technology, with a strong intellectual property portfolio and a focus on food, pharmaceutical, and cannabis industries [8]. - The company has over fifty partners across twenty-four countries, utilizing its technology to create innovative products and improve existing offerings [9]. - EnWave's strategy includes signing royalty-bearing commercial licenses with food producers to enhance drying efficiency and product quality [10].

Core Viewpoint - Decibel Cannabis Company Inc. reported strong financial results for Q2 2025, showcasing significant growth in both domestic and international markets, driven by the integration of AgMedica and successful marketing initiatives [2][6]. Financial Performance - Gross Canadian recreational sales reached CAD 38.2 million in Q2 2025, up from CAD 33.6 million in Q2 2024, marking a 14.5% increase [5]. - Net Canadian recreational sales were CAD 23.7 million, a 7% increase year-over-year [6]. - International sales surged to CAD 6.1 million, a significant increase from CAD 37, representing a 16,500% year-over-year growth [5][6]. - Total gross revenue for Q2 2025 was CAD 44.4 million, compared to CAD 33.7 million in Q2 2024, reflecting a 32% increase [5]. - Net revenue for the quarter was CAD 29.8 million, a 35% increase compared to CAD 22.2 million in Q2 2024 [6]. Profitability Metrics - Gross profit before fair value adjustments was CAD 14.0 million, with a gross margin of 47%, up from 42% in Q2 2024 [5][6]. - Adjusted EBITDA for Q2 2025 was CAD 6.3 million, a 60% increase year-over-year [6]. - Free cash flow improved to CAD 2.2 million, a year-over-year increase of CAD 4.3 million [6]. Strategic Developments - The successful integration of AgMedica has established a robust international platform for Decibel, enhancing its global market presence [2]. - The company anticipates strong international demand and plans to expand its contracts and volumes in the second half of 2025 [6]. Operational Highlights - Decibel operates three cultivation facilities and a processing center, positioning itself as a leader in high-quality cannabis products [11]. - The company has executed additional contracts for cannabis exports, with expectations for increased volumes in future periods [6].

Core Viewpoint - Cannara Biotech Inc. has amended its credit facility with Bank of Montreal to include a $10 million upsize, aimed at funding the initial post-harvest expansion at its Valleyfield facility, which supports the company's long-term goal of achieving an annual production capacity of 100,000 kg [1][5]. Financial Flexibility and Growth Strategy - The amendments to the credit facility reflect confidence in Cannara's growth strategy and operational performance, as stated by the President & CEO [2]. - The company is positioned to execute the expansion of its Valleyfield facility with improved financial flexibility and reduced financing costs, while maintaining a strong balance sheet [3]. Capital Expenditures Facility - The Restated Credit Facility includes a $10 million committed delayed capital expenditures debt facility, available through multiple draws until July 2026, with a 10-year amortization schedule [4]. - This facility will fund the initial phase of Cannara's post-harvest expansion, enhancing capabilities in hang-drying, freezing, trimming, packaging, and butane extraction [5]. Interest Rate Reduction - Cannara secured a total 50-basis-point reduction in the interest rate spread under the Restated Credit Facility, decreasing the overall cost of debt from over 8% in 2024 to below 6% [8]. - The company achieved this reduction through meeting certain covenant thresholds, resulting in significant savings in interest expenses [8]. Removal of Limited Recourse Guarantee - The company successfully eliminated a limited recourse guarantee provided by a related party, which reduced annual interest expense by approximately $375,000, thereby strengthening its capital structure [8].

Core Insights - High Tide Inc. (HITI) is entering the German medical cannabis market by acquiring a majority stake in Remexian, indicating a strategic expansion into Europe [1] Company Developments - The acquisition of Remexian marks a significant move for High Tide Inc. as it seeks to establish a foothold in the growing European medical cannabis sector [1] Market Context - The entry into the German market aligns with the increasing demand for medical cannabis in Europe, presenting potential growth opportunities for companies in this sector [1]

Company Strategy - Scotts Miracle-Gro 开发了一系列针对合法大麻种植者的植物产品线 [1] - 该公司对大麻合法化的十年押注最初看起来很明智 [1] Market Trends - 随着各州相继将大麻合法化，市场前景广阔 [1] - 大麻市场的发展并非一帆风顺，面临挑战 [1]

Core Viewpoint - TerrAscend Corp. has authorized a renewal of its normal course issuer bid (NCIB) to repurchase up to USD $10 million of its common shares over a 12-month period, reflecting confidence in the company's value amid regulatory momentum in the cannabis sector [1][2]. Share Repurchase Program - The new NCIB allows for the repurchase of up to 10 million shares, representing 4.73% of the public float based on 306 million shares outstanding as of August 14, 2025 [3][4]. - The previous NCIB, which started on August 22, 2024, resulted in the repurchase of 1,279,400 shares for approximately $616,000 (CAD$855,000) at an average price of $0.47 (CAD$0.67) per share [2][4]. - The company is not obligated to repurchase shares and may suspend or terminate the program at its discretion if better uses for cash reserves are identified [3][4]. Market Context - The company operates in the North American cannabis sector, with interests in multiple states including Pennsylvania, New Jersey, Maryland, Ohio, Michigan, and California [5]. - TerrAscend's operations include cultivation, processing, and retail through brands such as The Apothecarium and Gage, providing a diverse product selection for both medical and adult-use markets [5]. Regulatory Environment - The cannabis industry in the United States is subject to significant legal restrictions, as cannabis remains a Schedule I drug under federal law, which poses risks to operations [6][7]. - Despite a trend toward non-enforcement of federal laws against compliant state programs, strict adherence to state laws does not absolve the company from federal liability [7].

Core Insights - Vext Science, Inc. reported record financial results for Q2 2025, with revenue reaching $13.4 million, a 59% increase year-over-year, and a strong cash flow margin of 31% [4][7][3] Financial Performance - Revenue for Q2 2025 was $13,407,000, compared to $11,561,000 in Q1 2025 and $8,427,000 in Q2 2024 [3] - Adjusted EBITDA for Q2 2025 was $4,077,000, up from $3,357,000 in Q1 2025 and $1,084,000 in Q2 2024, reflecting a significant year-over-year increase [3][13] - Operating cash flow for Q2 2025 was $4,175,000, compared to $(592,000) in Q2 2024 and $3,082,000 in Q1 2025, indicating improved operational efficiency [3][11] Market Dynamics - The growth in revenue and adjusted EBITDA was driven by strong performance in Ohio, where retail sales increased by 86% sequentially [4][7] - Vext is on track to reach the state dispensary license cap of eight by early 2026, enhancing its market presence in Ohio [7][22] Operational Highlights - The company maintained profitability in Arizona despite market contraction by focusing on sell-through on its own retail shelves [4] - Vext's disciplined operations and scalable footprint contributed to its strong cash flow generation and overall financial health [4][7] Recent Developments - Vext completed the acquisition of two cannabis dispensaries in Ohio, which contributed to the revenue growth in Q2 2025 [12] - The company has plans to open additional dispensaries, including a new location in Fairfield, Ohio, expected to begin operations in Q4 2025 [12][22]